Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;78(11):1545-1549.
doi: 10.1136/annrheumdis-2019-215707. Epub 2019 Jul 30.

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts

Anne Boel  1 , Anna Molto  2 , Désirée van der Heijde  3 , Adrian Ciurea  4 , Maxime Dougados  2   5 , Lianne S Gensler  6 , Maria-José Santos  7 , Eugenio De Miguel  8 , Denis Poddubnyy  9   10 , Martin Rudwaleit  11 , Astrid van Tubergen  12   13 , Floris A van Gaalen  3 , Sofia Ramiro  3   14
Affiliations
Free article

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts

Anne Boel et al. Ann Rheum Dis. 2019 Nov.
Free article

Abstract

Background: Patients with spondyloarthritis with radiographic sacroiliitis are traditionally classified according to the modified New York (mNY) criteria as ankylosing spondylitis (AS) and more recently according to the Assessment of SpondyloArthritis international Society (ASAS) criteria as radiographic axial spondyloarthritis (r-axSpA).

Objective: To investigate the agreement between the mNY criteria for AS and the ASAS criteria for r-axSpA and reasons for disagreement.

Methods: Patients with back pain ≥3 months diagnosed as axSpA with radiographic sacroiliitis (mNY radiographic criterion) were selected from eight cohorts (ASAS, Esperanza, GESPIC, OASIS, Reuma.pt, SCQM, SPACE, UCSF). Subsequently, we calculated the percentage of patients who fulfilled the ASAS r-axSpA criteria within the group of patients who fulfilled the mNY criteria and vice versa in six cohorts with complete information.

Results: Of the 3882 patients fulfilling the mNY criteria, 93% also fulfilled the ASAS r-axSpA criteria. Inversely, of the 3434 patients fulfilling the ASAS r-axSpA criteria, 96% also fulfilled the mNY criteria. The main cause for discrepancy between the two criteria sets was the reported age at onset of back pain.

Conclusion: Almost all patients with axSpA with radiographic sacroiliitis fulfil both ASAS and mNY criteria, which supports the interchangeable use of the terms AS and r-axSpA.

Keywords: ankylosing spondylitis; epidemiology; outcomes research; spondyloarthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AM reports grants and speaker/consultancy fees from AbbVie, Pfizer, BMS, UCB and Merck, outside the submitted work; DvdH reports speaker/consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB outside the submitted work and is the Director of Imaging Rheumatology bv.; EDM reports grants and speaker/consultancy fees from AbbVie, BMS, MSD, Novartis, Pfizer, Roche and UCB outside the submitted work; DP reports grants and speaker/consultancy fees from AbbVie, MSD, Novartis and Pfizer and speaker/consultancy fees from BMS, Lilly, Roche, UCB and Celgene outside the submitted work; MR reports speaker/consultancy fees from AbbVie, BMS, Celgene, Chugai, Eli-Lily, Janssen, MSD, Novartis, Pfizer and UCB outside the submitted work; AvT reports grants from Pfizer, AbbVie, UCB and Biogen and grants and speaker/consultancy fees from Novartis outside the submitted work; FAvG reports grants from MSD, Novartis, AbbVie, the Dutch Arthritis Society, Stichting Vrienden van Sole Mio, UCB and Pfizer outside the submitted work; SR reports speaker/consultancy fees from AbbVie, Eli-Lilly, Novartis and Sanofi and grants and speaker/consultancy fees from MSD outside the submitted work. AB, AC, MD, LG and MJS have nothing to disclose. GESPIC has been financially supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung—BMBF), as part of the German competence network in rheumatology (Kompetenznetz Rheuma). As funding by BMBF was reduced according to schedule in 2005 and stopped in 2007, complementary financial support has been obtained also from Abbott/Abbvie, Amgen, Centocor, Schering-Plough and Wyeth. Since 2010 GESPIC is supported by Abbvie, additional support has been obtained also from ArthroMark (grants number FKZ 01EC1401A) and METARTHROS (grant number FKZ 01EC1407A) projects funded by BMBF.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types